Charles  Farkas net worth and biography

Charles Farkas Biography and Net Worth

Director of CONMED

Mr. Farkas has spent more than 40 years at Bain & Company. He became an Advisory Partner of Bain & Company on July 1, 2015. Prior to this, Mr. Farkas was a Senior Partner at Bain & Company, served as the Global Co-Head of Bain’s Healthcare Practice, and advised leading medical technology and pharmaceutical companies in the United States, Europe, and Asia. He also advised academic medical centers and provider organizations in the United States. Mr. Farkas advised chief executives and senior managers in a wide variety of industries on issues critical to long-term success, including strategy, mergers and acquisitions, and operational effectiveness. He has served as the managing director of Bain Canada and as the global leader of Bain & Company’s Financial Services practice. Prior to working at Bain, Mr. Farkas received a Bachelor of Arts degree from Princeton University and a Masters in Business Administration from Harvard Business School.

Mr. Farkas is also on the board of John A. Hartford Foundation, and from 2005 to 2017 was on the board of the Harvard Medical School. Mr. Farkas is on the board of Intuitive Healthcare, a portfolio company of Altamont Capital Partners. Mr. Farkas also serves on the board of United Bridge Partners, an infrastructure fund dedicated solely to financing, building, owning, and operating toll bridges for cities, towns, counties, and states, and serves as Chair of the Board of Medicinal Genomics, a venture backed life science company in plant genomics. The Board of Directors has determined that Mr. Farkas is independent within the meaning of the rules of the New York Stock Exchange.

Mr. Farkas’ qualifications for election to CONMED’s Board include his significant years of healthcare and medical technology experience gained working around the world. Mr. Farkas is a highly respected leader and he provides the Board with valuable strategic and governance perspectives, drawing on his vast experience inside and outside the healthcare industry. He has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

What is Charles Farkas' net worth?

The estimated net worth of Charles Farkas is at least $656.29 thousand as of September 12th, 2025. Farkas owns 14,859 shares of CONMED stock worth more than $656,292 as of December 5th. This net worth estimate does not reflect any other assets that Farkas may own. Learn More about Charles Farkas' net worth.

How do I contact Charles Farkas?

The corporate mailing address for Farkas and other CONMED executives is 525 FRENCH ROAD, UTICA NY, 13502. CONMED can also be reached via phone at (727) 392-6464. Learn More on Charles Farkas' contact information.

Has Charles Farkas been buying or selling shares of CONMED?

Charles Farkas has not been actively trading shares of CONMED during the last ninety days. Most recently, Charles Farkas sold 2,000 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $53.52, for a transaction totalling $107,040.00. Following the completion of the sale, the director now directly owns 14,859 shares of the company's stock, valued at $795,253.68. Learn More on Charles Farkas' trading history.

Who are CONMED's active insiders?

CONMED's insider roster includes Martha Aronson (Chair of the Board), Pat Beyer (Insider), Brian Concannon (Director), Charles Farkas (Director), Todd Garner (CFO), Richard Glaze (Chief Information Officer), Curt Hartman (Chairman of the Board, CEO & President), Daniel Jonas (Insider), John Kennedy (EVP), Stanley Peters, III (VP), Barbara Schwarzentraub (Director), Peter Shagory (EVP), and Mark Tryniski (Director). Learn More on CONMED's active insiders.

Are insiders buying or selling shares of CONMED?

In the last twelve months, insiders at the sold shares 4 times. They sold a total of 6,514 shares worth more than $362,185.92. The most recent insider tranaction occured on November, 21st when insider Richard Glaze sold 257 shares worth more than $10,590.97. Insiders at CONMED own 3.1% of the company. Learn More about insider trades at CONMED.

Information on this page was last updated on 11/21/2025.

Charles Farkas Insider Trading History at CONMED

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/12/2025Sell2,000$53.52$107,040.0014,859View SEC Filing Icon  
5/5/2025Sell4,000$56.94$227,760.0016,346View SEC Filing Icon  
See Full Table

Charles Farkas Buying and Selling Activity at CONMED

This chart shows Charles Farkas's buying and selling at CONMED by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CONMED Company Overview

CONMED logo
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Read More

Today's Range

Now: $44.17
Low: $43.72
High: $44.89

50 Day Range

MA: $44.87
Low: $40.53
High: $48.79

2 Week Range

Now: $44.17
Low: $40.16
High: $76.34

Volume

447,048 shs

Average Volume

509,528 shs

Market Capitalization

$1.37 billion

P/E Ratio

21.55

Dividend Yield

1.80%

Beta

0.98